Filing Details

Accession Number:
0000950170-24-025906
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-05 16:10:22
Reporting Period:
2024-03-01
Accepted Time:
2024-03-05 16:10:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA In Vitro & In Vivo Diagnostic Substances (2835) 364785571
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1792726 James Basta C/O Intellia Therapeutics, Inc.
40 Erie Street; Suite 130
Cambridge MA 02139
Evp, General Counsel No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-01 32,394 $0.00 83,868 No 4 A Direct
Common Stock Disposition 2024-03-04 2,297 $32.99 81,571 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-03-01 46,752 $0.00 46,752 $32.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
46,752 2034-02-28 No 4 A Direct
Footnotes
  1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
  2. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2024, and does not represent a volitional trade by the Reporting Person.
  3. This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.